MedTrace Logo

Long Term Immune Memory Responses to HPV Vaccination Following 2 vs 3 Doses of Quad-HPV Vaccine

NCT02968420 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 18

Last updated 2021-06-25

Study results available
· View outcomes & findings →

Summary

The overall aim of this study is to further understand the memory response to HPV vaccination in subjects who have received 2 versus 3 doses of quadrivalent HPV vaccine. Although memory responses can be detected shortly after immunization, the best approach to measure the long-lasting anamnestic response is to challenge with a booster dose years (\> 5) after the original exposure.

Conditions

  • Human Papillomavirus

Interventions

BIOLOGICAL

Human Papillomavirus 9-valent Vaccine, Recombinant

All groups will receive a single dose of the Gardasil9 vaccine at Visit 1/Day 0 of the study.

Sponsors & Collaborators

  • Merck Canada Inc.

    collaborator INDUSTRY

  • University of British Columbia

    lead OTHER

Principal Investigators

  • Tobi Kollmann, MD PhD · Vaccine Evaluation Center, University of British Columbia

  • Manish Sadarangani, BM BCh DPhil · Vaccine Evaluation Center, University of British Columbia

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
17 Years
Max Age
35 Years
Sex
FEMALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2017-09-11
Primary Completion
2019-05-15
Completion
2019-05-15

Countries

  • Canada

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02968420 on ClinicalTrials.gov